AVITA Medical Sells $1.5M in Stock

TL;DR

AVITA Medical just sold 1M shares at $1.50 for $1.5M cash, using it for general ops.

AI Summary

AVITA Medical, Inc. reported on August 12, 2025, that it entered into a Securities Purchase Agreement on August 12, 2025, for the unregistered sale of 1,000,000 shares of its common stock at a price of $1.50 per share. This transaction is expected to result in gross proceeds of approximately $1.5 million before deducting offering expenses. The company intends to use these proceeds for general corporate purposes.

Why It Matters

AVITA Medical is raising capital through a private placement, which could fund operations or strategic initiatives, but also dilutes existing shareholders.

Risk Assessment

Risk Level: medium — The sale of unregistered securities at a discount can indicate potential financial pressure or a need for quick capital, and it dilutes existing shareholders.

Key Numbers

• 1,000,000 — Shares Sold (Under unregistered sale of equity securities)
• $1.50 — Price Per Share (For unregistered sale of equity securities)
• $1.5 million — Gross Proceeds (Expected from the unregistered sale of equity securities)

Key Players & Entities

• AVITA Medical, Inc. (company) — Registrant
• August 12, 2025 (date) — Date of Securities Purchase Agreement and earliest event reported
• 1,000,000 (dollar_amount) — Number of shares sold
• $1.50 (dollar_amount) — Price per share
• $1.5 million (dollar_amount) — Gross proceeds from the sale

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar
• $1.32 — ), at an issue price of approximately AU$1.32 per CDI, with five CDIs representing on
• $15 million — e aggregate proceeds of approximately US$15 million (A$22.7 million) and to pay placement a
• $22.7 million — oceeds of approximately US$15 million (A$22.7 million) and to pay placement agent fees, in a
• $0.8 m — and CDIs, for an approximate value of US$0.8 million, in connection with the Placement

Filing Documents

• rcel-20250812.htm (8-K) — 41KB
• 0001762303-25-000026.txt ( ) — 148KB
• rcel-20250812.xsd (EX-101.SCH) — 25KB
• rcel-20250812_htm.xml (XML) — 5KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. On August 12, 2025, AVITA Medical, Inc. (the "Company") entered into a placement agreement (the "Placement Agreement") with MST Financial Services Pty Limited for a placement (the "Placement") to Australian institutional and professional investors of 17,201,886 CHESS Depositary Interests ("CDIs"), at an issue price of approximately AU$1.32 per CDI, with five CDIs representing one share of Common Stock. The Company expects to receive aggregate proceeds of approximately US$15 million (A$22.7 million) and to pay placement agent fees, in a combination of cash and CDIs, for an approximate value of US$0.8 million, in connection with the Placement. The Placement is expected to close on or about August 19, 2025. The CDIs to be issued and sold in the Placement will be deemed to be securities exempt from registration under the Securities Act of 1933, as amended, in reliance on Regulation S promulgated thereunder, as transactions by an issuer in an offering made outside the United States. Legends or notices will be affixed to the securities issued in reliance on Regulation S.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc Date: August 18, 2025 By: /s/ David O'Toole David O'Toole Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR